Online inquiry

IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15025MR)

This product GTTS-WQ15025MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF1R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001288705.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1436
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15025MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10775MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ14010MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ14099MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ15010MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ7170MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ13094MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ8636MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ7818MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK 716155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW